Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India

Trial Profile

Randomised Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 08 Oct 2021 Results comparing vaccine efficacy of single dose to that of three and two doses in protecting against persistent HPV 16 and 18 infection at 10 years post vaccination, published in the Lancet Oncology.
    • 23 Jul 2020 Results of pooled analysis of data from 2 trials (NCT00128661 and NCT00923702), assessing the serological assays to monitor antibody responses to single dose HPV vaccines, published in the Vaccine
    • 31 Aug 2016 Planned End Date changed from 1 May 2017 to 1 Jul 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top